Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2001 Oct;109(Suppl 5):791–796. doi: 10.1289/ehp.01109s5791

Residential and recreational acquisition of possible estuary-associated syndrome: a new approach to successful diagnosis and treatment.

R C Shoemaker 1
PMCID: PMC1240613  PMID: 11677191

Abstract

Evidence suggests that the estuarine dinoflagellates, Pfiesteria piscicida Steidinger & Burkholder and P. shumwayae Glasgow & Burkholder, members of the toxic Pfiesteria complex (TPC), may release one or more toxins that kill fish and adversely affect human health. In the current study we investigated the potential for undiagnosed cases of possible estuary-associated syndrome (PEAS), as termed by the Centers for Disease Control and Prevention (CDC), in a population that had residential and/or recreational exposure to TPC-affected estuaries, but that did not have direct contact with fish kills or lesioned fish. Age-adjusted visual contrast sensitivity (VCS) was significantly lower and the presence of PEAS-associated symptoms was much higher in the estuary cohort (n = 77) than in combined-control cohorts (n = 87), one without exposure to bodies of water (n = 53) and one with exposure to marine waters (n = 34). In the estuary cohort, 37 individuals met the CDC case definition for PEAS and had significantly lower VCS than non-PEAS cases. The VCS improved and symptoms abated after 2 weeks of treatment with cholestyramine. Cholestyramine, the original drug approved for treatment of hypercholesterolemia, has previously been reported to enhance the elimination rates of a variety of toxins, presumably by interruption of enterohepatic recirculation through toxin entrapment in its polymeric structure and/or anion-exchange process. Control studies showed that repeated VCS testing alone did not improve VCS scores and that cholestyramine treatment did not affect VCS in patients with elevated cholesterol levels. These results suggested that a) susceptible individuals may acquire PEAS through residential and/or recreational contact with TPC-affected estuaries in the absence of an active fish kill; b) VCS is a useful indicator in PEAS diagnosis and treatment monitoring; and c) PEAS can be effectively treated with cholestyramine. Because the study did not use population sampling techniques, the results do not indicate PEAS prevalence. Furthermore, definitive diagnosis of PEAS and association with TPC toxin(s) must await identification of, and a serologic test for, the putative TPC toxin(s).

Full Text

The Full Text of this article is available as a PDF (567.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen T., Andersen J. R., Tvede M., Franzmann M. B. Collagenous colitis: are bacterial cytotoxins responsible? Am J Gastroenterol. 1993 Mar;88(3):375–377. [PubMed] [Google Scholar]
  2. Boylan J. J., Egle J. L., Guzelian P. S. Cholestyramine: use as a new therapeutic approach for chlordecone (kepone) poisoning. Science. 1978 Feb 24;199(4331):893–895. doi: 10.1126/science.74852. [DOI] [PubMed] [Google Scholar]
  3. Brouillard M. Y., Rateau J. G. La cholestyramine fixe les toxines d'Escherichia coli et de Vibrio cholerae par une liaison ionique. Ann Gastroenterol Hepatol (Paris) 1990 Jan-Feb;26(1):27–30. [PubMed] [Google Scholar]
  4. Bungay P. M., Dedrick R. L., Matthews H. B. Pharmacokinetics of halogenated hydrocarbons. Ann N Y Acad Sci. 1979 May 31;320:257–270. doi: 10.1111/j.1749-6632.1979.tb56607.x. [DOI] [PubMed] [Google Scholar]
  5. Burkholder J. M., Noga E. J., Hobbs C. H., Glasgow H. B., Jr, Smith S. A. New 'phantom' dinoflagellate is the causative agent of major estuarine fish kills. Nature. 1992 Jul 30;358(6385):407–410. doi: 10.1038/358407a0. [DOI] [PubMed] [Google Scholar]
  6. Cohn W. J., Boylan J. J., Blanke R. V., Fariss M. W., Howell J. R., Guzelian P. S. Treatment of chlordecone (Kepone) toxicity with cholestyramine. Results of a controlled clinical trial. N Engl J Med. 1978 Feb 2;298(5):243–248. doi: 10.1056/NEJM197802022980504. [DOI] [PubMed] [Google Scholar]
  7. Creppy E. E., Baudrimont I., Betbeder A. M. Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Toxicol Lett. 1995 Dec;82-83:869–877. doi: 10.1016/0378-4274(95)03601-6. [DOI] [PubMed] [Google Scholar]
  8. Dahlem A. M., Hassan A. S., Swanson S. P., Carmichael W. W., Beasley V. R. A model system for studying the bioavailability of intestinally administered microcystin-LR, a hepatotoxic peptide from the cyanobacterium Microcystis aeruginosa. Pharmacol Toxicol. 1989 Feb;64(2):177–181. doi: 10.1111/j.1600-0773.1989.tb00625.x. [DOI] [PubMed] [Google Scholar]
  9. Fairey E. R., Edmunds J. S., Deamer-Melia N. J., Glasgow H., Jr, Johnson F. M., Moeller P. R., Burkholder J. M., Ramsdell J. S. Reporter gene assay for fish-killing activity produced by Pfiesteria piscicida. Environ Health Perspect. 1999 Sep;107(9):711–714. doi: 10.1289/ehp.99107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Glasgow H. B., Jr, Burkholder J. M., Schmechel D. E., Tester P. A., Rublee P. A. Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. J Toxicol Environ Health. 1995 Dec;46(4):501–522. doi: 10.1080/15287399509532051. [DOI] [PubMed] [Google Scholar]
  11. Grattan L. M., Oldach D., Perl T. M., Lowitt M. H., Matuszak D. L., Dickson C., Parrott C., Shoemaker R. C., Kauffman C. L., Wasserman M. P. Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet. 1998 Aug 15;352(9127):532–539. doi: 10.1016/S0140-6736(98)02132-1. [DOI] [PubMed] [Google Scholar]
  12. Hudnell H. K., Boyes W. K., Otto D. A., House D. E., Creason J. P., Geller A. M., Darcey D. J., Broadwell D. K. Battery of neurobehavioral tests recommended to ATSDR: solvent-induced deficits in microelectronic workers. Toxicol Ind Health. 1996 Mar-Apr;12(2):235–243. [PubMed] [Google Scholar]
  13. Hudnell H. K. Effects from environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Neurotoxicology. 1999 Apr-Jun;20(2-3):379–397. [PubMed] [Google Scholar]
  14. Hudnell H. K., House D., Schmid J., Koltai D., Stopford W., Wilkins J., Savitz D. A., Swinker M., Music S. Human visual function in the North Carolina clinical study on possible estuary-associated syndrome. J Toxicol Environ Health A. 2001 Apr 20;62(8):575–594. doi: 10.1080/15287390151079633. [DOI] [PubMed] [Google Scholar]
  15. Hudnell H. K., Otto D. A., House D. E. The influence of vision on computerized neurobehavioral test scores: a proposal for improving test protocols. Neurotoxicol Teratol. 1996 Jul-Aug;18(4):391–400. doi: 10.1016/0892-0362(96)00040-2. [DOI] [PubMed] [Google Scholar]
  16. Hudnell H. K., Skalik I., Otto D., House D., Subrt P., Sram R. Visual contrast sensitivity deficits in Bohemian children. Neurotoxicology. 1996 Fall-Winter;17(3-4):615–628. [PubMed] [Google Scholar]
  17. Humphrey C. D., Condon C. W., Cantey J. R., Pittman F. E. Partial purification of a toxin found in hamsters with antibiotic-associated colitis. Reversible binding of the toxin by cholestyramine. Gastroenterology. 1979 Mar;76(3):468–476. [PubMed] [Google Scholar]
  18. Kerkadi A., Barriault C., Tuchweber B., Frohlich A. A., Marquardt R. R., Bouchard G., Yousef I. M. Dietary cholestyramine reduces ochratoxin A-induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxin. J Toxicol Environ Health A. 1998 Feb 6;53(3):231–250. doi: 10.1080/009841098159367. [DOI] [PubMed] [Google Scholar]
  19. Levin E. D., Rezvani A. H., Christopher N. C., Glasgow H. B., Jr, Deamer-Melia N. J., Burkholder J. M., Moser V. C., Jensen K. Rapid neurobehavioral analysis of Pfiesteria piscicida effects in juvenile and adult rats. Neurotoxicol Teratol. 2000 Jul-Aug;22(4):533–540. doi: 10.1016/s0892-0362(00)00080-5. [DOI] [PubMed] [Google Scholar]
  20. Levin E. D., Schmechel D. E., Burkholder J. B., Deamer-Melia N. J., Moser V. C., Harry G. J. Persisting learning deficits in rats after exposure to Pfiesteria piscicida. Environ Health Perspect. 1997 Dec;105(12):1320–1325. doi: 10.1289/ehp.971051320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Levin E. D., Simon B. B., Schmechel D. E., Glasgow H. B., Jr, Deamer-Melia N. J., Burkholder J. M., Moser V. C., Jensen K., Harry G. J. Pfiesteria toxin and learning performance. Neurotoxicol Teratol. 1999 May-Jun;21(3):215–221. doi: 10.1016/s0892-0362(98)00041-5. [DOI] [PubMed] [Google Scholar]
  22. Levin E. D., Simon B. B., Schmechel D. E., Glasgow H. B., Jr, Deamer-Melia N. J., Burkholder J. M., Moser V. C., Jensen K., Harry G. J. Pfiesteria toxin and learning performance. Neurotoxicol Teratol. 1999 May-Jun;21(3):215–221. doi: 10.1016/s0892-0362(98)00041-5. [DOI] [PubMed] [Google Scholar]
  23. Liacouras C. A., Piccoli D. A. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol. 1996 Apr;22(3):186–189. doi: 10.1097/00004836-199604000-00007. [DOI] [PubMed] [Google Scholar]
  24. Moncino M. D., Falletta J. M. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol. 1992 Nov;14(4):361–364. [PubMed] [Google Scholar]
  25. Mutter L. C., Blanke R. V., Jandacek R. J., Guzelian P. S. Reduction in the body content of DDE in the Mongolian gerbil treated with sucrose polyester and caloric restriction. Toxicol Appl Pharmacol. 1988 Mar 15;92(3):428–435. doi: 10.1016/0041-008x(88)90182-2. [DOI] [PubMed] [Google Scholar]
  26. Rateau J. G., Brouillard M., Morgant G., Aymard P. Etude expérimentale chez le lapin de l'effet de la cholestyramine dans le traitement des diarrhées infectieuses d'origine cholérique. Ann Gastroenterol Hepatol (Paris) 1986 Oct;22(5):289–296. [PubMed] [Google Scholar]
  27. Shoemaker R. C. Diagnosis of Pfiesteria-human illness syndrome. Md Med J. 1997 Nov-Dec;46(10):521–523. [PubMed] [Google Scholar]
  28. Shoemaker R. C., Hudnell H. K. Possible estuary-associated syndrome: symptoms, vision, and treatment. Environ Health Perspect. 2001 May;109(5):539–545. doi: 10.1289/ehp.01109539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shoemaker R. Treatment of persistent Pfiesteria-human illness syndrome. Md Med J. 1998 Feb-Mar;47(2):64–66. [PubMed] [Google Scholar]
  30. Swinker M., Koltai D., Wilkins J., Hudnell K., Hall C., Darcey D., Robertson K., Schmechel D., Stopford W., Music S. Estuary-associated syndrome in North Carolina: an occupational prevalence study. Environ Health Perspect. 2001 Jan;109(1):21–26. doi: 10.1289/ehp.0110921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Underhill K. L., Rotter B. A., Thompson B. K., Prelusky D. B., Trenholm H. L. Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice. Bull Environ Contam Toxicol. 1995 Jan;54(1):128–134. doi: 10.1007/BF00196279. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES